Volume 56, Issue 1, Pages (July 2009)

Slides:



Advertisements
Similar presentations
Volume 58, Issue 5, Pages (November 2010)
Advertisements

Volume 61, Issue 5, Pages (May 2012)
The PSA Era is not Over for Prostate Cancer
Volume 50, Issue 1, Pages (July 2006)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
European Urology Focus
Volume 63, Issue 2, Pages (February 2013)
Volume 70, Issue 1, Pages (July 2016)
Testosterone Therapy in Men With Prostate Cancer
2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections  Rodolfo Montironi,
Volume 67, Issue 4, Pages (April 2015)
Volume 57, Issue 3, Pages e22-e23 (March 2010)
Volume 60, Issue 1, Pages (July 2011)
Volume 74, Issue 2, Pages (August 2018)
Testosterone and Prostate Cancer: Revisiting Old Paradigms
Volume 53, Issue 5, Pages (May 2008)
Volume 69, Issue 4, Pages (April 2016)
Volume 69, Issue 1, Pages (January 2016)
Let the Games Begin (with EAU Approval)
Volume 73, Issue 5, Pages (May 2018)
Volume 64, Issue 3, Pages (September 2013)
Prostate Cancer Epidemic in Sight?
Volume 58, Issue 1, Pages (July 2010)
John P. Mulhall, Francesco Montorsi  European Urology 
Volume 63, Issue 4, Pages e53-e56 (April 2013)
Volume 189, Issue 1, Pages (January 2013)
Adeno-associated Virus Serotype Vectors Efficiently Transduce Normal Prostate Tissue and Prostate Cancer Cells  Jianzhong Ai, Dan Wang, Qiang Wei, Hong.
Volume 68, Issue 1, Pages 5-7 (July 2015)
Volume 66, Issue 4, Pages (October 2014)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Detection: A View of the Future
Volume 68, Issue 3, Pages (September 2015)
Volume 67, Issue 3, Pages (March 2015)
Next-generation Sequencing of Urologic Cancers: Next Is Now
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Volume 50, Issue 4, Pages (October 2006)
Rodolfo Montironi, Ming Zhou, Cristina Magi-Galluzzi, Jonathan I
Volume 54, Issue 6, Pages (December 2008)
Volume 70, Issue 1, Pages (July 2016)
Volume 56, Issue 2, Pages (August 2009)
International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia  Brett Delahunt, John R. Srigley, Lars Egevad,
Volume 52, Issue 2, Pages (August 2007)
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Volume 59, Issue 3, Pages e7-e8 (March 2011)
Volume 61, Issue 5, Pages (May 2012)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 68, Issue 6, Pages e134-e135 (December 2015)
Volume 64, Issue 6, Pages (December 2013)
Volume 70, Issue 3, Pages e72-e74 (September 2016)
TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential  Liang Cheng, Rodolfo Montironi,
Volume 62, Issue 3, Pages (September 2012)
Volume 50, Issue 5, Pages (November 2006)
Volume 55, Issue 6, Pages (June 2009)
2005 Update on Pathology of Prostate Biopsies with Cancer
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 69, Issue 5, Pages (May 2016)
Volume 66, Issue 6, Pages (December 2014)
Volume 63, Issue 2, Pages (February 2013)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
European Urology is “Your” Journal
The Start-Up of the Platinum Journal: A Fascinating Challenge
Profile of Silodosin European Urology Supplements
Volume 53, Issue 6, Pages (June 2008)
Volume 54, Issue 1, Pages (July 2008)
Volume 53, Issue 2, Pages (February 2008)
Pathological Findings in TRUS Prostatic Biopsy—Diagnostic, Prognostic and Therapeutic Importance  Rodolfo Montironi, Roberta Mazzucchelli, Vincenzo Scattoni,
Volume 51, Issue 5, Pages (May 2007)
2005 Update on Pathology of Prostate Biopsies with Cancer
Presentation transcript:

Volume 56, Issue 1, Pages 105-112 (July 2009) Overexpression of ELAV-like Protein HuR is Associated with Increased COX-2 Expression in Atrophy, High-grade Prostatic Intraepithelial Neoplasia, and Incidental Prostate Cancer in Cystoprostatectomies  Francesca Barbisan, Roberta Mazzucchelli, Alfredo Santinelli, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli, Francesco Montorsi, Rodolfo Montironi  European Urology  Volume 56, Issue 1, Pages 105-112 (July 2009) DOI: 10.1016/j.eururo.2008.04.043 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 (A–D) HuR staining in normal looking prostate epithelium (A), atrophy (B), high-grade prostatic intraepithelial neoplasia adjacent to normal epithelium (C), and prostatic adenocarcinoma (D). Staining is also present in the nuclei of the stromal cells. (E–H) COX-2 staining in normal looking prostate epithelium (E), atrophy (F), high-grade prostatic intraepithelial neoplasia (G), and prostatic adenocarcinoma (H). European Urology 2009 56, 105-112DOI: (10.1016/j.eururo.2008.04.043) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 HuR staining in the cytoplasm of the secretory cells in normal looking epithelium (NEp), (remote or away from and adjacent to PCa), atrophy (remote or away from and adjacent to PCa), high-grade prostatic intraepithelial neoplasia (HGPIN) (remote or away from and adjacent to PCa), and prostatic adenocarcinoma (PCa) in the cystoprostatectomy (CyP) and radical prostatectomy (RP) specimens. There is an increase in the percentage of cells with cytoplasmic staining from NEp to atrophy, HGPIN, and PCa. (The columns represent the mean; the standard error is also shown.) European Urology 2009 56, 105-112DOI: (10.1016/j.eururo.2008.04.043) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 HuR staining of strong intensity in the cytoplasm of the secretory cells. The values increase progressively from atrophy away from PCa towards PCa. Normal looking epithelium (NEp) shows cells with strong intensity neither remote from nor adjacent to PCa. (The columns represent the mean; the standard error is also shown.) European Urology 2009 56, 105-112DOI: (10.1016/j.eururo.2008.04.043) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 4 HuR staining in the nuclei of the secretory cells. There is a trend towards a reduced nuclear expression in atrophy, HGPIN, and PCa, compared to NEp. (The columns represent the mean; the standard error is also shown.) European Urology 2009 56, 105-112DOI: (10.1016/j.eururo.2008.04.043) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 5 COX-2 staining in the cytoplasm of the basal cells. There is reduction in the proportion of positive cells from NEp to atrophy and HGPIN. (The columns represent the mean; the standard error is also shown.) European Urology 2009 56, 105-112DOI: (10.1016/j.eururo.2008.04.043) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 6 COX-2 staining in the cytoplasm of the secretory cells. There is increase in the percentage of secretory cells with cytoplasmic staining from NEp to atrophy, HGPIN, and PCa. (The columns represent the mean; the standard error is also shown.) European Urology 2009 56, 105-112DOI: (10.1016/j.eururo.2008.04.043) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 7 COX-2 staining of strong intensity in the cytoplasm of the secretory cells. The values increase from atrophy away from PCa towards PCa. Normal looking epithelium (NEp) shows cells with strong intensity neither remote from nor adjacent to PCa. (The columns represent the mean; the standard error is also shown.) European Urology 2009 56, 105-112DOI: (10.1016/j.eururo.2008.04.043) Copyright © 2008 European Association of Urology Terms and Conditions